One important metric to look for in a stock is an 80 or higher Relative Strength Rating. SpringWorks Therapeutics now clears that threshold, with a jump from 77 to 85 Wednesday.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's proprietary RS Rating tracks technical performance by showing how a stock's price action over the last 52 weeks measures up against that of the other stocks in our database.
Decades of market research shows that the market's biggest winners typically have an RS Rating north of 80 as they begin their biggest runs.
While it's not currently an ideal time to jump in, see if the stock goes on to offer and clear an appropriate buy point.
SpringWorks Therapeutics posted 0% earnings growth last quarter. Revenue gains came in at 1,029%. The company is expected to report its latest results on or around May 1.
The company earns the No. 71 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and GeneDx Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Technical Action?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
